– USA, IL – Quetzal Therapeutics, a biopharmaceutical company focused on developing transformative therapies for patients with rare and life-threatening diseases, announced the appointment of Todd Smith to its Board of Directors, bringing more than three decades of leadership experience across the pharmaceutical and medical device industries, with a proven track record of driving business transformation, organizational growth, and operational excellence.
About Todd Smith
Known for his innovative, strategic, and execution-focused approach, Todd Smith has helped raise more than $1 billion in capital, led 25+ product launches, and executed over 100 business development/M&A deals.
In addition to his current role as CEO of Corium, Todd Smith has held numerous executive leadership positions, including CEO of Valinor, Iroko Pharmaceuticals, Zyla Life Sciences, and Assertio Therapeutics, as well as CCO and Head of Business Development at Horizon Therapeutics and Tolmar Pharma. Beyond his executive experience, he has also founded more than 10 healthcare companies and currently serves on several boards, including BVI Medical, ApolloCare, and Corium Therapeutics.
Todd Smith holds a B.A. in Political Science from Norwich University.
About Quetzal Therapeutics
Quetzal Therapeutics is a biopharmaceutical company focused on the development of treatments for rare diseases, including hematologic malignancies. The company’s lead product is QTX-2101, a novel paradigm for treating patients with Acute Promyelocytic Leukemia (APL). The company plans to initiate Phase III clinical trials by late 2025, with enabling activities ongoing. Quetzal is also developing a pre-clinical asset, QTX-2102, an advanced, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity.
For more information: https://quetzaltx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.